"Since 1996, the physicians of Digestive Disease Associates (DDA) have been committed to providing quality medical care for the diagnosis and treatment of gastrointestinal and liver disease. Patients throughout Maryland, Pennsylvania, Virginia and Washington, D.C., have benefited from the patient-centered care delivered by our board certified gastroenterologists. Digestive Disease Associates offers a full range of specialized medical services which focus on all aspects of gastroenterology (stomach and intestines) and hepatology (liver-related) disorders. Treatment is provided in one of our two state-of-the-art endoscopy and infusion centers."

During the past decade, Digestive Disease Associates, PA conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 32 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 16 clinical trials were completed. i.e. 228.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Digestive Disease Associates, PA" #1 sponsor was "Gilead Sciences" with 17 trials, followed by "Bristol-Myers Squibb" with 12 trials sponsored, "Celgene" with 6 trials sponsored, "Enanta Pharmaceuticals, Inc" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Digestive Disease Associates, PA" #1 collaborator was "Pharmaceutical Research Associates" with 2 trials as a collaborator, "Triangle Biostatistics" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Schering-Plough" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Digestive Disease Associates, PA" are "Hepatitis C" (8 trials), "Ulcerative Colitis" (6 trials), "Chronic Hepatitis B" (5 trials), "Hepatitis C Virus" (5 trials) and "Nonalcoholic Steatohepatitis" (5 trials). Many other conditions were trialed in "Digestive Disease Associates, PA" in a lesser frequency.

Most popular intervention types in "Digestive Disease Associates, PA" are "Drug" (54 trials), "Biological" (4 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Daclatasvir" (6 trials), "RBV" (4 trials), "Ribavirin" (4 trials) and "Sofosbuvir" (4 trials). Other intervention names were less common.

The vast majority of trials in "Digestive Disease Associates, PA" are 60 trials for "All" genders.

Currently, there are NaN active trials in "Digestive Disease Associates, PA". undefined are not yet recruiting, 7 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 45 completed trials in Digestive Disease Associates, PA, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Digestive Disease Associates, PA, 1 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".